Apr 16 |
Cullinan Therapeutics expands into autoimmune diseases
|
Apr 16 |
Cullinan Therapeutics gets $280M via oversubscribed private placement
|
Apr 16 |
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
|
Apr 16 |
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
|
Apr 16 |
Cullinan changes name, pivots to autoimmune disease
|
Mar 16 |
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 15 |
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
|
Mar 14 |
Cullinan Oncology GAAP EPS of -$0.54
|
Mar 14 |
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 1 |
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
|